|Awarded On||August 18, 2021|
|Title||A Preclinical Development Core for Large Molecule Therapeutics|
|Award Mechanism||Core Facility Support Awards|
|Institution/Organization||The University of Texas Health Science Center at Houston|
|Principal Investigator/Program Director||Qingyun Liu|
|Cancer Sites||All Sites|
*Pending contract negotiation
Monoclonal antibodies are now the predominant form of cancer drugs. Antibody-drug conjugates (ADCs) which are the combination of antibodies and cytotoxins are emerging as a new class of highly effective oncology drugs. Antibodies and ADCs are considered large molecule therapeutics due to their molecular size, and their discovery and development is rapidly gaining momentum in the state as CPRIT funded more and more such efforts. Several key capabilities are required to discover and develop novel large molecule drugs, including scale-up production, pharmacokinetic analysis, and toxicology studies. Results of pharmacokinetics and toxicology studies provide important guidance in selecting t...